Medical Oncology, Год журнала: 2022, Номер 39(9)
Опубликована: Июнь 18, 2022
Язык: Английский
Frontiers in Oncology, Год журнала: 2022, Номер 11
Опубликована: Янв. 25, 2022
Tumors have special features that make them distinct from their normal counterparts. Immature cells in a tumor mass and critical contributions to the tumorigenesis will open new windows toward cancer therapy. Incomplete cellular development brings versatile unique functionality ecosystem, such as what is seen for highly potential embryonic cells. There evidence maturation of certain types this ecosystem can recover sensitivity tumor. Therefore, understanding more about mechanisms contributed immaturity render therapeutic approaches Targeting be exploited supplementary current immunotherapeutic treatment schedules, immune checkpoint inhibitor (ICI) The key focus review discuss impact (im)maturity ecosystems on progression, focusing mainly cell compartment tumor, well stemness
Язык: Английский
Процитировано
33
Pathology - Research and Practice, Год журнала: 2023, Номер 247, С. 154528 - 154528
Опубликована: Май 9, 2023
Язык: Английский
Процитировано
20
Pharmaceuticals, Год журнала: 2024, Номер 17(2), С. 201 - 201
Опубликована: Фев. 2, 2024
The underdevelopment of adjuvant discovery and diversity, compared to core vaccine technology, is evident. On the other hand, antibiotic resistance on list top ten threats global health. Immunomodulatory peptides that target a pathogen modulate immune system simultaneously are promising for development preventive therapeutic molecules. Since investigating innate immunity in insects has led prominent achievements human immunology, such as toll-like receptor (TLR) discovery, we used capacity immunomodulatory arthropods with concomitant antimicrobial or antitumor activity. An SVM-based machine learning classifier identified short sequences encrypted 643 from 55 foe-to-friend arthropods. critical features involved efficacy safety were calculated. Finally, 76 safe immunomodulators identified. Then, molecular docking simulation studies defined most optimal peptide ligands among all cell-surface TLRs. SPalf2-453 crab cell-penetrating immunoadjuvant antiviral properties. interacts TLR1/2 heterodimer. SBsib-711 blackfly TLR4/MD2 ligand cancer immunoadjuvant. In addition, binds CD47 PD-L1 tumor cells, which applicable immunotherapy checkpoint inhibitor. MRh4-679 shrimp broad-spectrum universal putative Th1/Th2-balanced response. We also implemented pathway enrichment analysis define fingerprints immunological signatures further vitro vivo immunogenicity reactogenicity measurements. Conclusively, combinatorial learning, docking, studies, well systems biology, open new opportunity multifunctional prophylactic lead peptides.
Язык: Английский
Процитировано
7
International Journal of Clinical Oncology, Год журнала: 2021, Номер 27(1), С. 45 - 58
Опубликована: Ноя. 13, 2021
Язык: Английский
Процитировано
36
Frontiers in Immunology, Год журнала: 2022, Номер 13
Опубликована: Сен. 2, 2022
The development and response to treatment of tumor are modulated by inflammation, chronic inflammation promotes progression therapy resistance. This article summarizes the dynamic evolution from acute in process development, its effect on T cells activation promotion exhaustion. We review mechanisms which inflammatory cytokines regulate cell exhaustion methods for targeting improve efficacy immunotherapy. It is great significance refer specific state at different stages accurate clinical decision-making immunotherapy improving efficiency
Язык: Английский
Процитировано
25
Polymer Reviews, Год журнала: 2024, Номер 64(3), С. 818 - 871
Опубликована: Март 8, 2024
Chitosan is cancer cytotoxic. It induces apoptosis/necrosis/autophagy and immuno-responses, mitigates angiogenic metastasis tendency of cells. The lower molecular weight chitosan apoptosis, whereas the higher exerts apoptosis necrosis. Transforming into nanoparticles raises its anti-cancer efficacy with mode cell death governed by particle size to a greater extent than weight. larger tend exert apoptosis. smaller mediate "Drug-free" small constituted are more cytotoxic those molecules/particles in vitro vivo, no clear relationship between deacetylation degree zeta potential nanoparticulate activity. potentially as viable drug-loaded but reduced systemic adverse effects. Their can be modulated through dose adjustment risks harmful effects drugs without processing hurdles faced development such low aqueous drug solubility, poor encapsulation, premature release absorption, instability toxic metabolite formation.
Язык: Английский
Процитировано
6
Current Treatment Options in Oncology, Год журнала: 2024, Номер 25(8), С. 1073 - 1088
Опубликована: Июль 27, 2024
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2022, Номер 13
Опубликована: Апрель 1, 2022
Dysregulated innate and adaptive immunity is a sign of SARS-CoV-2-induced disease cancer. CD8 + T cells are important the immune system. The belong to take front-line defense against viral infections Extreme T-cell activities in lung patients with within tumor microenvironment (TME) will change their functionality into exhausted state undergo apoptosis. Such diminished put cancer cases at high-risk group for disease, rendering sepsis more severe condition which finally cause higher rate mortality. Recovering responses from purpose vaccination SARS-CoV-2. aim this review discuss cellular present some strategies recovering these critical cells.
Язык: Английский
Процитировано
20
Biomedicine & Pharmacotherapy, Год журнала: 2022, Номер 158, С. 114150 - 114150
Опубликована: Дек. 26, 2022
Resistance to immune checkpoint inhibitors (ICIs) is a major issue of the current era in cancer immunotherapy. Immune evasion multi-factorial event, which occurs generally at base cold immunity. Despite advances field, there are still unsolved challenges about how combat hijacked by tumor cells and what complementary treatment strategies render durable anti-tumor outcomes. A point that anti-programed death-1 receptor (PD-1)/anti-programmed death-ligand 1 (PD-L1) not solo path escape, responses many types solid tumors PD-1/PD-L1 satisfactory. Thus, seeking mechanisms inter-connecting with its ecosystem nearby unravel more resistance so as develop methods for sustained reinvigoration activity against cancer. In this review, we aimed discuss common specific paths taken evade surveillance, describing novel detection strategies, well suggesting some approaches recover sensitivity anti-PD-(L)1 therapy based on knowledge.
Язык: Английский
Процитировано
19
Pharmaceutics, Год журнала: 2023, Номер 15(4), С. 1134 - 1134
Опубликована: Апрель 3, 2023
Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there great need for development of other disease-targeted therapies. Due, in part, to profound immunosuppressive microenvironment seen GBMs, has been broad interest immunotherapy. In both GBMs cancers, therapeutic vaccines have generally yielded limited efficacy, despite their theoretical basis. However, recent results from DCVax-L trial provide some promise vaccine therapy GBMs. There also potential that future combination therapies with adjuvant immunomodulating agents may greatly enhance antitumor immune responses. Clinicians must remain open novel strategies, such as vaccinations, carefully await ongoing trials. this review GBM management, challenges immunotherapy focus on vaccinations are discussed. Additionally, therapies, logistical considerations, directions
Язык: Английский
Процитировано
11